New flu vaccine shows promise in south korean trial
NCT ID NCT05144945
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 26 times
Summary
This study tested a new quadrivalent recombinant influenza vaccine (RIV4) against a standard quadrivalent inactivated flu vaccine (Fluarix Quadrivalent) in 301 healthy adults aged 18 and older in South Korea. The goal was to see how well the new vaccine triggers the immune system and to check its safety. Results showed both vaccines produced strong antibody responses, with the new vaccine being a safe and effective option for flu prevention.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA (HEALTHY VOLUNTEERS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :4100001
Seoul, Seoul-teukbyeolsi, 152-703, South Korea
-
Investigational Site Number :4100002
Seoul, 07441, South Korea
-
Investigational Site Number :4100003
Ansan-si, Gyeonggi-do, 15355, South Korea
Conditions
Explore the condition pages connected to this study.